9% Increase in Test Volume; 5% Increase in Total Revenue CMS Announces Gapfill Pricing Methodology for Oncotype DX® Breast Cancer Test's Unique CPT Code
Positive Ductal Carcinoma In Situ (DCIS) Clinical Validation Study Accepted for Oral Presentation at 2014 CTRC-AACR San Antonio Breast Cancer Symposium Two Clinical Studies Using NGS-based Proprietary Liquid Biopsy Platform to Detect Presence of Breast and Bladder Cancers to be Presented at Upcoming Medical Meetings Conference Call Today at 4:30 p.m. ET REDWOOD CITY, Calif.
PRINCETON, NJ and REHOVOT, ISRAEL and BOTHELL, WA --
BlackBerry Limited (NASDAQ: BBRY; TSX: BB), a global leader in mobile
communications, and NantHealth, a cloud-based information technology
provider combining science and big data to transform healthcare, today
announced the first secure clinical genome browser that gives doctors
unprecedented access to patients’ genetic data on the BlackBerry®
Passport smartphone – the NantOmics Cancer Genome Browser™.
The NantOmics Cancer Genome Browser platform on the BlackBerry Passport
enables deep, interactive reporting on genomics data for physicians and
other treatment providers in clinical settings – for example, giving
oncologists a powerful view into the individual genetic alternations
that make each patient’s disease unique and highlighting relevant
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.